IHEEZO- chloroprocaine hydrochloride ophthalmic gel gel

IHEEZO by

Drug Labeling and Warnings

IHEEZO by is a Prescription medication manufactured, distributed, or labeled by Harrow Eye, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    IHEEZO TM is indicated for ocular surface anesthesia.

  • 2 DOSAGE AND ADMINISTRATION

    The recommended dose of IHEEZO TM is 3 drops applied topically to the ocular surface in the area of the planned procedure. IHEEZO TM may be reapplied as needed to maintain anesthetic effect.

  • 3 DOSAGE FORMS AND STRENGTHS

    IHEEZO TM (chloroprocaine hydrochloride ophthalmic gel) 3% contains 24 mg of chloroprocaine hydrochloride per vial (800 mg of gel).

  • 4 CONTRAINDICATIONS

    IHEEZO TM is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Not for Injection or Intraocular Administration

    IHEEZO TM should not be injected or intraocularly administered.

    5.2 Corneal Injury Due to Insensitivity

    Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.

    5.3 Corneal Opacification

    Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.

    5.4 Risk of Contamination

    Do not touch the dropper tip to any surface as this may contaminate the gel.

    5.5 For Administration by Healthcare Provider

    IHEEZO TM is indicated for administration under the direct supervision of a healthcare provider. IHEEZO TM is not intended for patient self-administration.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The data described below reflect 201 patients undergoing various surgical ocular procedures in two placebo-controlled trials (Study 1 and Study 2). Patients in Study 1 were randomized to receive a single instillation of 3 drops of IHEEZO TM or placebo. Patients in Study 2 were randomized to receive a single or multiple instillations of 1, 3 or 3+3 drops of IHEEZO TM or placebo.

    The most common adverse reactions in these studies, (incidence greater than or equal to 5%) following IHEEZO TM administration were mydriasis, conjunctival hyperemia and eye irritation.

    Adverse Reactions Reported in Controlled Trials

    Table 1. Adverse Reactions in 5% or more of IHEEZO TM Treated Patients in Studies 1 and 2

    IHEEZO TMPlacebo
    Preferred Term

    N=151

    n (%)

    N=50

    n (%)

    Mydriasis39 (26%)

    1 (2%)
    Conjunctival hyperemia16 (11%)6 (12%)
    Eye irritation9 (6%)2 (4%)

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no adequate and well-controlled studies of IHEEZO TM use in pregnant women to inform a drug associated risk. There are no animal reproduction studies for chloroprocaine.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of chloroprocaine in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for IHEEZO TM and any potential adverse effects on the breastfed infant from IHEEZO TM.

    8.4 Pediatric Use

    The safety and effectiveness of IHEEZO TM have not been established in pediatric patients.

    8.5 Geriatric Use

    No overall differences in safety or effectiveness of IHEEZO TM have been observed between elderly and younger patients.

  • 11 DESCRIPTION

    IHEEZO TM is a sterile, single-patient‑use ophthalmic gel preparation for topical ocular anesthesia containing chloroprocaine hydrochloride as the active pharmaceutical ingredient. Chloroprocaine hydrochloride is an ester anesthetic. It is a water-soluble white crystalline powder and its chemical name is 2-(Diethylamino)ethyl 4‑amino-2-chlorobenzoate monohydrochloride. The molecular weight is 307.22 and the molecular formula is C 13H 19ClN 2O 2·HCl. It is represented by the following structural formula:

    chemstru

    IHEEZO TM contains:

    Active: 30 mg of chloroprocaine hydrochloride (equivalent to 26 mg of chloroprocaine) per gram of gel.

    Inactive ingredients: Hydroxyethyl Cellulose (HEC), and Water for Injection. The pH may be adjusted to 3.0 to 5.0 with Hydrochloric Acid. This product does not contain an antimicrobial preservative.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.1 Mechanism of Action

    Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

    12.3 Pharmacokinetics

    The systemic exposure to chloroprocaine following topical ocular administration of IHEEZO TM has not been studied.

    Elimination

    Metabolism

    Chloroprocaine is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues. Chloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase. The hydrolysis of chloroprocaine results in the production of ß-diethylaminoethanol and 2-chloro-4-aminobenzoic acid, which inhibits the action of the sulfonamides.

    Excretion

    Chloroprocaine plasma half-life in vitro is approximately 25 seconds in adults and approximately 43 seconds in neonates. The kidney is the main excretory organ for most local anesthetics and their metabolites. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Long-term studies in animals to evaluate carcinogenic potential of chloroprocaine have not been conducted.

    Mutagenesis

    2-chloroprocaine and the main metabolite, ACBA, were negative in the in vitro bacterial reverse mutation test (Ames assay) and the in vitro chromosome aberrations assay.

    Impairment of Fertility

    Studies in animals to evaluate the impairment of fertility have not been conducted with chloroprocaine.

  • 14 CLINICAL STUDIES

    14.1 Study 1 and 2

    Study 1 (NCT04779606) and Study 2 (NCT04753710) were randomized, double-blinded placebo-controlled studies conducted to evaluate the efficacy, safety, and local tolerability of IHEEZO TM in 145 healthy volunteers.

    In Study 1, 85 healthy male and female were randomized in a 4:1 ratio to receive a single ocular instillation of IHEEZO TM (N=68) or placebo (N=17). The double blinded treatment included a IHEEZO TM or a placebo dose of 3 drops instilled at 1 minute ± 15 seconds intervals in the right eye of each volunteer. The median age was 39 years (range 19 to 55 years); 59% female and 41% male.

    In Study 2, 60 healthy male and female were randomized (40:20) to receive single or multiple ocular instillations of IHEEZO TM dose of 3 drops in the right eye. The median age was 25 years (range 18 to 59 years); 54% female ad 46% male.

    The efficacy in Study 1 and 2 was determined by proportion of patients achieving full conjunctival anesthesia evaluated by conjunctival pinching, 5 minutes after administration.

    Efficacy results of Study 1

    The proportion of subjects with successful anesthesia was 90% in IHEEZO TM group and 12% in the placebo group (p<0.01). The median time for the IHEEZO TM group achieving anesthesia was 0.67 minutes. The median duration of anesthesia was 14.3 minutes.

    Efficacy results of Study 2

    The proportion of subjects with successful anesthesia was 95% in the IHEEZO TM group and 20% in the placebo group (p<0.01). The median time for the IHEEZO TM group achieving anesthesia was 0.67 minutes. The median duration of anesthesia was 19.3 minutes.

    14.2 Study 3

    Study 3 (NCT04685538) was a randomized, prospective, multi-center, active-controlled, observer-masked study conducted to evaluate the efficacy and safety of IHEEZO TM (N=166) versus tetracaine ophthalmic solution 0.5% (N=172) in patients undergoing cataract surgery.

    The primary endpoint was defined as the proportion of patients in each treatment group gaining successful anesthesia without any supplementation. On average, patients needed 1-1.5 minutes to obtain sufficient anesthesia to successfully perform the surgical procedure which lasted on average 22 minutes.

    No patient treated with IHEEZO TM required supplemental treatment to complete the intended surgical procedure.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    IHEEZO TM (chloroprocaine hydrochloride ophthalmic gel) 3% is supplied as a sterile, clear, colorless to light yellow gel in a single-patient‑use vial. Each single‑patient‑use vial contains 24 mg chloroprocaine in 800 mg of gel.

    Aluminum pouch containing 1 LDPE single-patient‑use vial of IHEEZO TM.

    The outer surface of the vial is not sterile.

    NDC: 82667-300-01 Package of 1 unit of 1.25 mL single-patient‑use vial (800 mg filled)

    NDC: 82667-300-10 Package of 10 units of 1.25 mL single-patient‑use vials (800 mg filled)

    NDC: 82667-300-00 Sample package of 1 unit of 1.25 mL single-patient-use vial (800 mg filled)

    Storage

    Store at 15°C to 25°C (59°F to 77°F).

    Discard after use.

  • 17 PATIENT COUNSELING INFORMATION

    Eye Care Precaution

    Do not touch the dropper tip to any surface as this may contaminate the gel.

    Advise patients that their eyes will be insensitive for up to 20 minutes due to the effect of the anesthetic, and that care should be taken to avoid accidental injuries.

  • SPL UNCLASSIFIED SECTION

    Manufactured by

    Laboratoire Unither

    1 Rue de l’Arquerie

    50200 COUTANCES

    France

    Distributed by

    Harrow Eye, LLC

    102 Woodmont Blvd. Suite 610

    Nashville, TN 37205

    USA

  • PRINCIPAL DISPLAY PANEL - Carton

    NDC: 82667-300-01 Sterile Rx Only

    Iheezo TM

    (chloroprocaine hydrochloride ophthalmic gel) 3%

    For topical ophthalmic use

    Contains no preservatives. 1 Vial 800 mg each HARROW ®

    carton

  • PRINCIPAL DISPLAY PANEL - Pouch

    NDC: 82667-300-01

    Iheezo TM

    (chloroprocaine hydrochloride ophthalmic gel) 3%

    To be administered by physician only.

    Single-Patient-Use Vial

    Discard unused portion.

    For topical ophthalmic use.

    Contains no preservatives.

    Sterile (outer surface of the vial not sterile)

    LOT: 1234

    EXP: YYYY-MM

    Rx Only

    Vial 800 mg

    pouch

  • PRINCIPAL DISPLAY PANEL - Sample Carton

    NDC: 82667-300-00

    Professional sample - Not for sale Sterile Rx Only

    Iheezo TM

    (chloroprocaine hydrochloride ophthalmic gel) 3%

    For topical ophthalmic use

    Contains no preservatives. 1 Vial 800 mg each HARROW ®

    Sample Carton

  • INGREDIENTS AND APPEARANCE
    IHEEZO 
    chloroprocaine hydrochloride ophthalmic gel gel
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 82667-300
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CHLOROPROCAINE HYDROCHLORIDE (UNII: LT7Z1YW11H) (CHLOROPROCAINE - UNII:5YVB0POT2H) CHLOROPROCAINE HYDROCHLORIDE24 mg  in 800 mg
    Inactive Ingredients
    Ingredient NameStrength
    HYDROXYETHYL CELLULOSE, UNSPECIFIED (UNII: T4V6TWG28D)  
    WATER (UNII: 059QF0KO0R)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 82667-300-011 in 1 CARTON09/27/2022
    11 in 1 POUCH
    1800 mg in 1 VIAL; Type 0: Not a Combination Product
    2NDC: 82667-300-001 in 1 CARTON03/15/2023
    21 in 1 POUCH
    2800 mg in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21622709/27/2022
    Labeler - Harrow Eye, LLC (118526951)

    • Trademark Results [IHEEZO]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    IHEEZO
    IHEEZO
    98402001 not registered Live/Pending
    Harrow IP, LLC
    2024-02-12
    IHEEZO
    IHEEZO
    97600469 not registered Live/Pending
    Harrow IP, LLC
    2022-09-21
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.